Understanding how adjuvant-autoantigen vaccines modulate IDO1 activity in human dendritic cells will facilitate improvements in combinatorial vaccine potency and safety, moving this effective immunosuppressive strategy closer to clinical applications for the prevention of autoimmunity and diseases that possess a strong chronic inflammatory component. This evidence concerns the gene IDO1 and Autoimmunity.